Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

NCT05691478 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05691478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05691478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Suspended
Start date
March 3, 2023
Completion date
March 20, 2030
Enrollment
1,122 (estimated)
Sites
202

Conditions

As the registry lists them; a condition with its own page is linked.

high grade osteosarcoma, localized osteosarcoma, metastatic osteosarcoma, secondary osteosarcoma